You are here

  • Home
  • Archive
  • Volume 78, Issue 5
  • Response to: ’A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease' by Aeschlimann et al

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ’A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease' by Aeschlimann et al
Free
  1. Florence A Aeschlimann1,2,
  2. Ronald M Laxer1,2,3
  1. 1 Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada
  2. 2 Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada
  3. 3 Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr Florence A Aeschlimann, Division of Rheumatology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; florence.aeschlimann{at}aphp.fr

https://doi.org/10.1136/annrheumdis-2018-213359

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Berteau et al 1 for sharing their experience of a family diagnosed with HA20 based on a Behçet-like disease phenotype and an autosomal-dominant inheritance pattern.

    The presentation and disease course described in the mother and her two children support the findings described in our cohort2 and in a recent large cohort of Japanese patients with HA20.3 An interesting observation presented by Dr Berteau et al is the development of high fever and a severe local inflammatory swelling following immunisation with an unconjugated anti-pneumococcal vaccine in the mother. While we did not observe such reactions in our cohort, they have also been reported in several Japanese patients with HA203 and in other autoinflammatory diseases such as the cryopyrin-associated periodic fever syndrome.

    This letter reinforces our observations and adds a new mutation c.[994G>T] p.Glu332* to the list of already known heterozygous TNFAIP3 mutations. In addition, it again highlights the need for clinicians to suspect HA20 in patients with Behçet-like disease phenotypes and the necessity for more research into this disease, from both clinical and basic research perspective. Of note, the patients included in our study were not all Americans, but Caucasians of Turkish, European, American and Dutch descent.

    References

    1. ↵
      2. Berteau F ,
      3. Rouvière B ,
      4. Nau A , et al
      . Response to: ‘A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease’. Ann Rheum Dis. In Press.doi:10.1136/annrheumdis-2018-213347
    2. ↵
      2. Aeschlimann FA ,
      3. Batu ED ,
      4. Canna SW , et al
      . A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis 2018;77:728–35.doi:10.1136/annrheumdis-2017-212403
      OpenUrlAbstract/FREE Full Text
    3. ↵
      2. Kadowaki T ,
      3. Ohnishi H ,
      4. Kawamoto N , et al
      . Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. J Allergy Clin Immunol 2017. 10.1016/j.jaci.2017.10.039. [Epub ahead of print 11 Dec 2017].doi:10.1016/j.jaci.2017.10.039

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors RML and FAA drafted, revised and approved the response to the eLetter. The co-authors of the initial publication' A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease' by Aeschlimann et al (ARD 2018) all approved the submitted response to the eLetter.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Not required.

    • Ethics approval The study was approved by the institutional research ethics board of the Hospital for Sick Children, Toronto (REB 1000053697).

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles